It exhibited higher antiproliferative activity than the reference compound, against Hep G2, A549 and KCC-853 cancer cell lines and also a higher inhibitory activity against C-Raf (for 69 C-Raf IC50 = 8.7 nM; for sorafenib C-Raf IC50 = 28.5 nM) [143]. This evidence concerns the gene RAF1 and cancer.